Enhanced phosphorylation of T153 in soluble tau is a defining biochemical feature of the A152T tau risk variant

Yari Carlomagno, Dah Eun Chloe Chung, Mei Yue, Aishe Kurti, Nicole M. Avendano, Monica Castanedes-Casey, Kelly M. Hinkle, Karen Jansen-West, Lillian M. Daughrity, Jimei Tong, Virginia Phillips, Rosa V Rademakers, Michael Deture, John D. Fryer, Dennis W Dickson, Leonard Petrucelli, Casey Cook

Research output: Contribution to journalArticle

Abstract

Pathogenic mutations in the tau gene (microtubule associated protein tau, MAPT) are linked to the onset of tauopathy, but the A152T variant is unique in acting as a risk factor for a range of disorders including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). In order to provide insight into the mechanism by which A152T modulates disease risk, we developed a novel mouse model utilizing somatic brain transgenesis with adeno-associated virus (AAV) to drive tau expression in vivo, and validated the model by confirming the distinct biochemical features of A152T tau in postmortem brain tissue from human carriers. Specifically, TauA152T-AAV mice exhibited increased tau phosphorylation that unlike animals expressing the pathogenic P301L mutation remained localized to the soluble fraction. To investigate the possibility that the A152T variant might alter the phosphorylation state of tau on T152 or the neighboring T153 residue, we generated a novel antibody that revealed significant accumulation of soluble tau species that were hyperphosphorylated on T153 (pT153) in TauA152T-AAV mice, which were absent the soluble fraction of TauP301L-AAV mice. Providing new insight into the role of A152T in modifying risk of tauopathy, as well as validating the TauA152T-AAV model, we demonstrate that the presence of soluble pT153-positive tau species in human postmortem brain tissue differentiates A152T carriers from noncarriers, independent of disease classification. These results implicate both phosphorylation of T153 and an altered solubility profile in the mechanism by which A152T modulates disease risk.

Original languageEnglish (US)
Number of pages1
JournalActa neuropathologica communications
Volume7
Issue number1
DOIs
StatePublished - Jan 23 2019

Fingerprint

Dependovirus
Phosphorylation
Tauopathies
Brain
Progressive Supranuclear Palsy
Lewy Body Disease
Gene Transfer Techniques
Mutation
Microtubule-Associated Proteins
Solubility
Alzheimer Disease
Antibodies
Genes

Keywords

  • A152T
  • Neuropathology
  • Phosphorylation
  • Risk factor
  • Solubility
  • Tauopathy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Enhanced phosphorylation of T153 in soluble tau is a defining biochemical feature of the A152T tau risk variant. / Carlomagno, Yari; Chung, Dah Eun Chloe; Yue, Mei; Kurti, Aishe; Avendano, Nicole M.; Castanedes-Casey, Monica; Hinkle, Kelly M.; Jansen-West, Karen; Daughrity, Lillian M.; Tong, Jimei; Phillips, Virginia; Rademakers, Rosa V; Deture, Michael; Fryer, John D.; Dickson, Dennis W; Petrucelli, Leonard; Cook, Casey.

In: Acta neuropathologica communications, Vol. 7, No. 1, 23.01.2019.

Research output: Contribution to journalArticle

Carlomagno, Yari ; Chung, Dah Eun Chloe ; Yue, Mei ; Kurti, Aishe ; Avendano, Nicole M. ; Castanedes-Casey, Monica ; Hinkle, Kelly M. ; Jansen-West, Karen ; Daughrity, Lillian M. ; Tong, Jimei ; Phillips, Virginia ; Rademakers, Rosa V ; Deture, Michael ; Fryer, John D. ; Dickson, Dennis W ; Petrucelli, Leonard ; Cook, Casey. / Enhanced phosphorylation of T153 in soluble tau is a defining biochemical feature of the A152T tau risk variant. In: Acta neuropathologica communications. 2019 ; Vol. 7, No. 1.
@article{a06ffea1aced448bb7423dc77eb19788,
title = "Enhanced phosphorylation of T153 in soluble tau is a defining biochemical feature of the A152T tau risk variant",
abstract = "Pathogenic mutations in the tau gene (microtubule associated protein tau, MAPT) are linked to the onset of tauopathy, but the A152T variant is unique in acting as a risk factor for a range of disorders including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). In order to provide insight into the mechanism by which A152T modulates disease risk, we developed a novel mouse model utilizing somatic brain transgenesis with adeno-associated virus (AAV) to drive tau expression in vivo, and validated the model by confirming the distinct biochemical features of A152T tau in postmortem brain tissue from human carriers. Specifically, TauA152T-AAV mice exhibited increased tau phosphorylation that unlike animals expressing the pathogenic P301L mutation remained localized to the soluble fraction. To investigate the possibility that the A152T variant might alter the phosphorylation state of tau on T152 or the neighboring T153 residue, we generated a novel antibody that revealed significant accumulation of soluble tau species that were hyperphosphorylated on T153 (pT153) in TauA152T-AAV mice, which were absent the soluble fraction of TauP301L-AAV mice. Providing new insight into the role of A152T in modifying risk of tauopathy, as well as validating the TauA152T-AAV model, we demonstrate that the presence of soluble pT153-positive tau species in human postmortem brain tissue differentiates A152T carriers from noncarriers, independent of disease classification. These results implicate both phosphorylation of T153 and an altered solubility profile in the mechanism by which A152T modulates disease risk.",
keywords = "A152T, Neuropathology, Phosphorylation, Risk factor, Solubility, Tauopathy",
author = "Yari Carlomagno and Chung, {Dah Eun Chloe} and Mei Yue and Aishe Kurti and Avendano, {Nicole M.} and Monica Castanedes-Casey and Hinkle, {Kelly M.} and Karen Jansen-West and Daughrity, {Lillian M.} and Jimei Tong and Virginia Phillips and Rademakers, {Rosa V} and Michael Deture and Fryer, {John D.} and Dickson, {Dennis W} and Leonard Petrucelli and Casey Cook",
year = "2019",
month = "1",
day = "23",
doi = "10.1186/s40478-019-0661-2",
language = "English (US)",
volume = "7",
journal = "Acta neuropathologica communications",
issn = "2051-5960",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Enhanced phosphorylation of T153 in soluble tau is a defining biochemical feature of the A152T tau risk variant

AU - Carlomagno, Yari

AU - Chung, Dah Eun Chloe

AU - Yue, Mei

AU - Kurti, Aishe

AU - Avendano, Nicole M.

AU - Castanedes-Casey, Monica

AU - Hinkle, Kelly M.

AU - Jansen-West, Karen

AU - Daughrity, Lillian M.

AU - Tong, Jimei

AU - Phillips, Virginia

AU - Rademakers, Rosa V

AU - Deture, Michael

AU - Fryer, John D.

AU - Dickson, Dennis W

AU - Petrucelli, Leonard

AU - Cook, Casey

PY - 2019/1/23

Y1 - 2019/1/23

N2 - Pathogenic mutations in the tau gene (microtubule associated protein tau, MAPT) are linked to the onset of tauopathy, but the A152T variant is unique in acting as a risk factor for a range of disorders including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). In order to provide insight into the mechanism by which A152T modulates disease risk, we developed a novel mouse model utilizing somatic brain transgenesis with adeno-associated virus (AAV) to drive tau expression in vivo, and validated the model by confirming the distinct biochemical features of A152T tau in postmortem brain tissue from human carriers. Specifically, TauA152T-AAV mice exhibited increased tau phosphorylation that unlike animals expressing the pathogenic P301L mutation remained localized to the soluble fraction. To investigate the possibility that the A152T variant might alter the phosphorylation state of tau on T152 or the neighboring T153 residue, we generated a novel antibody that revealed significant accumulation of soluble tau species that were hyperphosphorylated on T153 (pT153) in TauA152T-AAV mice, which were absent the soluble fraction of TauP301L-AAV mice. Providing new insight into the role of A152T in modifying risk of tauopathy, as well as validating the TauA152T-AAV model, we demonstrate that the presence of soluble pT153-positive tau species in human postmortem brain tissue differentiates A152T carriers from noncarriers, independent of disease classification. These results implicate both phosphorylation of T153 and an altered solubility profile in the mechanism by which A152T modulates disease risk.

AB - Pathogenic mutations in the tau gene (microtubule associated protein tau, MAPT) are linked to the onset of tauopathy, but the A152T variant is unique in acting as a risk factor for a range of disorders including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). In order to provide insight into the mechanism by which A152T modulates disease risk, we developed a novel mouse model utilizing somatic brain transgenesis with adeno-associated virus (AAV) to drive tau expression in vivo, and validated the model by confirming the distinct biochemical features of A152T tau in postmortem brain tissue from human carriers. Specifically, TauA152T-AAV mice exhibited increased tau phosphorylation that unlike animals expressing the pathogenic P301L mutation remained localized to the soluble fraction. To investigate the possibility that the A152T variant might alter the phosphorylation state of tau on T152 or the neighboring T153 residue, we generated a novel antibody that revealed significant accumulation of soluble tau species that were hyperphosphorylated on T153 (pT153) in TauA152T-AAV mice, which were absent the soluble fraction of TauP301L-AAV mice. Providing new insight into the role of A152T in modifying risk of tauopathy, as well as validating the TauA152T-AAV model, we demonstrate that the presence of soluble pT153-positive tau species in human postmortem brain tissue differentiates A152T carriers from noncarriers, independent of disease classification. These results implicate both phosphorylation of T153 and an altered solubility profile in the mechanism by which A152T modulates disease risk.

KW - A152T

KW - Neuropathology

KW - Phosphorylation

KW - Risk factor

KW - Solubility

KW - Tauopathy

UR - http://www.scopus.com/inward/record.url?scp=85060399730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060399730&partnerID=8YFLogxK

U2 - 10.1186/s40478-019-0661-2

DO - 10.1186/s40478-019-0661-2

M3 - Article

VL - 7

JO - Acta neuropathologica communications

JF - Acta neuropathologica communications

SN - 2051-5960

IS - 1

ER -